This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Current perspectives on mesenchymal stromal cell therapy for graft versus host disease
Cellular & Molecular Immunology Open Access 10 May 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579–1586.
Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS et al. Prochymal® improves response rates in patients with steroid-refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GvHD. Biol Blood Marrow Transplant 2010; 16: S169–S170.
Von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H et al. Long-Term Complications, Immunologic Effects and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy. Biol Blood Marrow Transplant 2012; 18: 557–564.
Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parodi R, Martínez C et al. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 2014; 20: 1580–1585.
Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric. Biol Blood Marrow Transplant 2014; 20: 375–381.
Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom A, Shimoni A et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013; 3: 225–238.
Gonzalo-Daganzo R, Regidor C, Martín-Donaire T, Rico MA, Bautista G, Krsnik I et al. Results of a pilot study on the use of third party donor mesenchymal stromal cells in cord blood transplantation in adults. mesenchymal stromal cells. Cytotherapy 2009; 3: 278–288.
Bernardo ME, Cometa AM, Pagliara D, Vinti L, Rossi F, Cristantielli R et al. Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol 2011; 24: 73–81.
von Bonin M, Stolzel F, Goedecke A, Rischter K, Wuschek N, Hölig K et al. Treatment of refractory acute GVHD with third party MSC expanded in platelet lysate containing medium. Bone Marrow Transplant 2009; 43: 245–251.
Fekete N, Rojewski MT, Fürst D, Kreja L, Ignatius A, Dausend J et al. GMP-compliant isolation and large scale expansion of bone marrow-derived MSC. PLoS ONE 2012; 7: e43255.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenback I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular therapy position statement. Cytotherapy 2006; 8: 315–317.
Munneke JM, Spruit MJ, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD . The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. Transplantation 2016; 100: 2309–2314.
Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang Ke et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21: 97–104.
von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N et al. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory GvHD: Clinical Responses and Long-Term Outcome. Stem Cells 2016; 34: 357–366.
Bernardo ME, Locatelli F . Mesenchymal Stromal Cells in Hematopoietic Stem Cell Transplantation. Methods Mol Biol 2016; 1416: 3–20.
Acknowledgements
Grants from EC Framework Programme 6 (AlloStem IP, contract LSHB-CT-2004-503319), Spanish Fondo de Investigaciones Sanitarias (PIO3/0961, PIO4/2794, PS09/1736), FIBHUPH and Fundación Lair.
Author contributions
CFM, RGD and JRCM are responsible for the conception and design of the study and wrote the initial draft of this manuscript. JRCM, MNF and RFD reviewed all text and figures. All authors contributed to the execution of the study, the analysis and/or interpretation of the data, reviewed and approved the manuscript contents for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Fernández-Maqueda, C., Gonzalo-Daganzo, R., Regidor, C. et al. Mesenchymal stromal cells for steroid-refractory acute GvHD. Bone Marrow Transplant 52, 1577–1579 (2017). https://doi.org/10.1038/bmt.2017.177
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.177
This article is cited by
-
Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial
Bone Marrow Transplantation (2024)
-
Current perspectives on mesenchymal stromal cell therapy for graft versus host disease
Cellular & Molecular Immunology (2023)
-
Understanding and treatment of cutaneous graft-versus-host-disease
Bone Marrow Transplantation (2023)
-
Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD
International Journal of Hematology (2021)
-
Infusion of Mesenchymal Stem Cells to Treat Graft Versus Host Disease: the Role of HLA-G and the Impact of its Polymorphisms
Stem Cell Reviews and Reports (2020)